For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6192Ka&default-theme=true
RNS Number : 6192K Oxford Nanopore Technologies plc 08 December 2025
Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
AGM Post-Meeting Shareholder Engagement Update
8 December 2025
In accordance with Provision 4 of the UK Corporate Governance Code, Oxford
Nanopore Technologies plc (LSE: ONT) is providing an update to the statements
made on 4 June 2025 in relation to the voting outcome of Resolution 12 at its
2025 Annual General Meeting ("AGM").
Following the AGM, the Company has undertaken an engagement exercise and
invited feedback from its major shareholders to understand why certain
shareholders were unable to support the resolution. The Board is grateful to
those shareholders who engaged with this process.
Feedback received from shareholders has been consistent with the Board's focus
on maximising the long-term potential of Oxford Nanopore. As previously
announced, the Company continues to refine its strategic planning process to
ensure it prioritises and executes on high-priority opportunities that best
leverage the unique capabilities of Oxford Nanopore's technology. This will
enable the Company to focus resources where it can create the greatest
long-term value for stakeholders.
The appointment of Francis Van Parys as Chief Executive Officer brings
extensive experience in scaling life-sciences businesses. Francis will lead
the next phase of the commercial strategy and will work closely with the Board
to deepen and strengthen the broader capability set across the management team
to support the next phase of growth and deliver long-term value for all
stakeholders.
-ENDS-
For further information please contact:
cosec@nanoporetech.com (mailto:cosec@nanoporetech.com)
ir@nanoporetech.com (mailto:ir@nanoporetech.com)
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries, to
understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer. Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.
For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END AGMGGBDDBUGDGUI
Copyright 2019 Regulatory News Service, all rights reserved